Journal of Vaccines & Vaccination

Novel oral targeted vaccines for cancer & pathogen challenges

International Conference & Exhibition on Vaccines & Vaccination

22-24 Nov 2011 Philadelphia Airport Marriott, USA

Mansour Mohamadzadeh

Keynote: J Vaccines Vaccin

Abstract:

V accines have been revolutionary eff ective to potentiate antibody avidity and T cell longevity, particularly in immune suppressive individuals. Despite worldwide vaccination against various devastating diseases, more than 20% of children are still left un- vaccinated resulting in approximately two million unnecessary deaths every year just because of the constraints on vaccine prod uction, distribution or the route of its delivery. To achieve a potent vaccine against microbial or cancer challenge, novel targeted and directional vaccine strategy should be de veloped to elicit roust mucosal and systemic immune responses against vaccine targets. Generating an oral and inexpensive vaccine that involves introduction of desired vaccine subunits into benefi cial commensal bacteria and its manufactureis one option, which would open new avenue in the fi eld. Such eff ort will include novel �?¯�?¿�?½targeting�?¯�?¿�?½ of the vaccine, evaluation of vaccine eff ectiveness against deadly pathogens, and the control of benefi cial commensal bacteria, including L. acidophilus gene expression that can readily be consumed to enable natural delivery of �?¯�?¿�?½targeted�?¯�?¿�?½ antigen to intestinal immune cells that elicit robust immunity against pathogens. Give n the fact that mucosal vaccines have an important role in immunotherapy of several infectious diseases (i.e., HIV), it is anticipate d that such an oral vaccine platform will serve as a foundation work for pursuing a role of a novel arm of immune system (i.e. mucosa l immune system) in the protection and the immunotherapy of various deadly pathogens

Biography :

Mansour Mohamadzadeh has completed his Ph.D at Johannes Gutenberg University in Mainz, Germany and Postdoctoral studies from Johannes Gutenberg, and SWMU University School of Medicine. He is a professor at Department of Infectious Diseases and Patholog y at University of Florida, Gainesville. He has published more than 60 papers in reputed journals. He is one of the leaders in va ccine and therapeutic strategies. His laboratory currently focus on two major research projects 1) to study the properties of novel adjuvants that induce the activation of mucosal DCs, and 2) to elucidate cellular and molec ular mechanisms that rebalance overt in fl ammatory immune responses induced by pathogenic commensal bacteria within the mucosal side